6 months ago
Ciltacabtagene Autoleucel (Carvykti) Approved by FDA for Second-Line Treatment of Relapsed or Refractory Multiple Myeloma Johnson & Johnson and Legend Biotech’s jointly developed chimeric...
6 months ago
Carvykti FDA Approval Press Release,Legend Biotech’s Carvykti Approved in the U.S. for Second-Line Treatment of Relapsed or Refractory Multiple Myeloma Carvykti is approved for second-line tr...
7 months ago
No Tumor Recurrence for Nearly 3 Years, China’s National Research #TIL Therapy #GC101 Targets Various Solid Tumors! TIL Therapy In recent years, immunotherapy has emerged as a pivotal di...
7 months ago
Carvykti EMA Approval for Second-Line Treatment of Multiple Myeloma Carvykti Receives CHMP Recommendation for Approval for Front-Line Treatment of Multiple Myeloma On February 23, 2024, Legend Biot...
7 months ago
Carvykti EU Approval on May 26, 2022 CARVYKTI® (Cilta-cel, Ciltacabtagene Autoleucel) Approved for Marketing in the European Union CARVYKTI® (Cilta-cel, Ciltacabtagene Autoleucel) is the first prod...
7 months ago
Will Carvykti(Ciltacabtagene Autoleucel) become one of the new standards of care for lenalidomide-refractory multiple myeloma Introduction to carvykti Carvykti (Ciltacabtagene Autoleucel, cilta-cel...
7 months ago
✈️ Thumbs Up for Visa-Free Policy: Off to China on a Whim! ✈️ Visa-Free Policy 🌏China expands its unilateral visa-free and mutual visa exemption policy. Starting from March 14, 2024, China implemen...
7 months ago
Research Progress of CAR-T Myeloma Therapy Multiple myeloma (MM) is a malignant plasma cell neoplasm characterized by the abnormal accumulation of monoclonal plasma cells in the bone marrow and the...
7 months ago
Understanding CAR-T Cells and Multiple Myeloma Therapy in One Read Many lymphoma and leukemia patients are familiar with CAR-T cell therapy, but for multiple myeloma patients, CAR-T cell therapy is...
7 months ago
A Successful Case of CAR-T Cell Immunotherapy for Multiple Myeloma in China At the Bone Marrow Transplantation Center of the First Affiliated Hospital of Zhejiang University School of Medicine in C...
7 months ago
🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉 Advanced Science Say hello to the future of cancer treatment! A groundbreaking mRNA cancer v...
7 months ago
Overview of Ciltacabtagene Autoleucel Approval Ciltacabtagene Autoleucel: An Overview of Its Approval Journey From 2014 to 2022, it took Ciltacabtagene Autoleucel eight years to complete the journe...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
